Viewing Study NCT02791334

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:39 AM
Ignite Modification Date: 2026-02-25 @ 7:04 PM
Study NCT ID: NCT02791334
Status: COMPLETED
Last Update Posted: 2024-09-27
First Post: 2016-06-01
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
Sponsor: Eli Lilly and Company
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Solid Tumor View
None Microsatellite Instability-High (MSI-H) Solid Tumors View
None Cutaneous Melanoma View
None Pancreatic Cancer View
None Breast Cancer (HR+HER2-) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PDL1 View
None PD-L1 View